Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma

Patrick J. Stiff, Ivana Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, Richard T. Maziarz, Brian J. Bolwell, Gary Bridger, Sachin Marulkar, Frank J. Hsu, John F. DiPersio

Research output: Contribution to journalArticle

61 Scopus citations


Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P < .001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P < .001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.

Original languageEnglish (US)
Pages (from-to)1146-1153
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number8
StatePublished - Aug 1 2011



  • Autologous peripheral blood stem cell transplantation
  • Cell dose
  • Platelet recovery
  • Plerixafor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this